Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NSCLC (Advanced Non-small Cell Lung Cancer): early-phase trial registry
4 of 4 indexed NSCLC (Advanced Non-small Cell Lung Cancer) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
NSCLC (Advanced Non-small Cell Lung Cancer): 4 US clinical trials tracked, 4 recruiting.
NSCLC (Advanced Non-small Cell Lung Cancer) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is BlossomHill Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition nsclc-advanced-non-small-cell-lung-cancer
OPEN 4 | RECR 100% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
NSCLC (Advanced Non-small Cell Lung Cancer) lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for NSCLC (Advanced Non-small Cell Lung Cancer) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
NSCLC (Advanced Non-small Cell Lung Cancer) is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Revolution Medicines
NCT06881784
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
BlossomHill Therapeutics
NCT06706076
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology
NCT07085091
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT05856981
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on NSCLC (Advanced Non-small Cell Lung Cancer) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on NSCLC (Advanced Non-small Cell Lung Cancer) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this NSCLC (Advanced Non-small Cell Lung Cancer) page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 NSCLC (Advanced Non-small Cell Lung Cancer) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BlossomHill Therapeutics sponsors the most NSCLC (Advanced Non-small Cell Lung Cancer) trials on record, review their full trial history before evaluating a specific study. See BlossomHill Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NSCLC (Advanced Non-small Cell Lung Cancer) condition card totals 4 registered trials; most-linked intervention BH-30643; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.